EMEA recommends the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride)

The European Medicines Agency (EMEA)The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation of Ionsys (fentanyl hydrochloride), from Janssen-Cilag International NV, because of a defect with the delivery system of the medicine that could lead to patients being overdosed.

Ionsys is a system for the transdermal delivery of fentanyl, an opioid analgesic. It has been authorised in the European Union (EU) since January 2006 and is indicated for the management in hospital of acute moderate to severe post-operative pain. The system is activated on demand by the patient in response to pain.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) was informed by the marketing authorisation holder, Janssen-Cilag International NV, that it had detected corrosion of a component of the system in one batch of Ionsys. This could trigger the self-activation of the system, which could lead to fentanyl overdose. This could subsequently cause respiratory depression, a life-threatening complication.

There have been no reports of serious adverse events associated with the malfunction of the device, in particular no reports related to self-activation of the system, or of overdose as a result. However, the marketing authorisation holder recalled all systems from the EU in September 2008 as a precautionary measure. As a consequence, Ionsys is unavailable and patients have been switched to alternative treatments.

The marketing authorisation holder has started a root-cause analysis of the defect, but has been unable to identify the cause of the defect. The company has also been unable to detect the defect with the quality control systems currently in place in the manufacturing and testing sites. In addition, the company's quality systems have been unable to resolve the problems with Ionsys and to prevent this quality defect occurring.

Because of this and the risks of fentanyl overdose, the CHMP has concluded that the benefits of Ionsys no longer outweigh its risks and has recommended the suspension of the marketing authorisation until the marketing authorisation holder can robustly demonstrate the quality of the product.

The CHMP opinion will now be sent to the European Commission for the adoption of a decision, applicable in all EU Member States.

More information on Ionsys is available in the European Public Assessment Report on the Agency's website at: http://www.emea.europa.eu/humandocs/Humans/EPAR/ionsys/ionsys.htm

For further information, please visit:
http://www.emea.europa.eu

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...